A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

544 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomised, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, tolerability, pharmacokinetics and immunogenicity of SB5 compared to Humira® in subjects with moderate to severe RA despite MTX therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects

NCT02144714

Healthy

COMPLETED PHASE1

A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

NCT01936181

Rheumatoid Arthritis

COMPLETED PHASE3

A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis

NCT02019472

Arthritis, Rheumatoid

COMPLETED PHASE3

A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

NCT04230213

Rheumatoid Arthritis

COMPLETED PHASE3

MSB11022 in Moderate to Severe Rheumatoid Arthritis

NCT03052322

Moderate to Severe Rheumatoid Arthritis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Investigational product: SB5 40 mg (0.8 mL of 50 mg/mL) Indication studied: Rheumatoid arthritis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SB5 (proposed biosimilar to adalimumab)

SB5 40 mg every other week via subcutaneous injection

Group Type EXPERIMENTAL

SB5 (proposed biosimilar to adalimumab)

Intervention Type DRUG

Humira (adalimumab)

Humira 40 mg every other week via subcutaneous injection

Group Type ACTIVE_COMPARATOR

Humira (adalimumab)

Intervention Type DRUG

SB5 (proposed biosimilar to adalimumab)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Humira (adalimumab)

Intervention Type DRUG

SB5 (proposed biosimilar to adalimumab)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are male or female aged 18-75 years at the time of signing the informed consent form.
* Have been diagnosed as having RA according to the revised 1987 American College of Rheumatology (ACR) criteria for at least 6 months but not exceeding 15 years prior to Screening.
* Have moderate to severe active disease despite MTX therapy defined as:

1. More than or equal to six swollen joints and more than or equal to six tender joints (from the 66/68 joint count system) at Screening and Randomisation.
2. Either erythrocyte sedimentation rate (Westergren) ≥ 28 mm/h or serum C-reactive protein ≥ 10 mg/dL at Screening.
* Must have been treated with MTX for a total of at least 6 months prior to Randomisation and must have been on both: a stable route of administration (oral or parenteral) and stable dose of MTX (10-25 mg/week) for at least 4 weeks prior to Screening.
* Female subjects who are not pregnant or nursing at Screening and Randomisation and who are not planning to become pregnant from Screening until 5 months after the last dose of IP.

Exclusion Criteria

* Have been treated previously with any biological agents including any tumour necrosis factor inhibitor.
* Have a known hypersensitivity to human immunoglobulin proteins or other components of Humira or SB5.
* Have a positive serological test for hepatitis B or hepatitis C or have a known history of infection with human immunodeficiency virus.
* Have a current diagnosis of active tuberculosis (TB), have been recently exposed to a person with active TB, or are considered to have latent TB.
* Have had a serious infection or have been treated with intravenous antibiotics for an infection within 8 weeks or oral antibiotics within 2 weeks prior to Randomisation.
* Have a history of chronic or recurrent infection.
* Have any of the following conditions:

1. History of congestive heart failure (New York Heart Association Class III/IV).
2. History of acute myocardial infarction or unstable angina within the previous 12 months prior to Screening.
3. History of demyelinating disorders.
4. History of any malignancy within the previous 5 years prior to Screening.
5. History of lymphoproliferative disease including lymphoma.
6. Any other disease or disorder which, in the opinion of the Investigator, will put the subject at risk if they are enrolled.
* Have physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound).

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No